John M. Kane provides commentary on the results of the Recovery After Initial Schizophrenic Episode – Early Treatment Program (RAISE-ETP) study. The trial compared coordinated specialty care to traditional care of 404 patients with a first-episode of psychosis in a community mental health center setting.
Samantha Sweeney, PharmD, MBA, is a Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. Sweeney received her PharmD from Rutgers University and MBA from the University of California at Irvine.
Mark Tacelosky, PharmD, is a Medical Science Liaison for Otsuka Pharmaceutical Development & Commercialization, Inc. Dr. Tacelosky received his PharmD from the University of the Sciences in Philadelphia.
John M. Kane, MD, is Senior Vice President for Behavioral Health Services at Northwell Health. He is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Hempstead, New York. He also serves as Chairman of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Dr. Kane received a BA from Cornell University and earned his medical degree from New York University School of Medicine. He completed his residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.
Speakers are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc.
Information included on the Patient & Caregiver Resources website is supported by PsychU. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC - committed supporters of the mental health treatment community. The resources provided are intended for your educational benefit only. Information is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Users seeking medical advice should consult with a health care professional.
MRC2.CORP.X.03855 / MRC2.CORP.X.03854